{"title":"进展期胃癌伴狭窄的肠造口术前化疗的探讨","authors":"Hidetaka A Ono, Yohei Ota, Hirokazu Suwa, Kazunori Nojiri, Kenichi Yoshida, Hidenobu Masui, Kaoru Nagahori","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Preoperative chemotherapy for gastric cancer with obstructive symptoms traditionally requires bypass surgery.</p><p><strong>Objective: </strong>To investigate the feasibility of preoperative enterostomy chemotherapy in patients with advanced gastric cancer who present with obstructive symptoms.</p><p><strong>Methods: </strong>A total of 47 patients with cStage Ⅲ gastric cancer who underwent preoperative chemotherapy between April 2013 and May 2024 were included. Patients with circumferential lesions underwent enterostomy during diagnostic laparoscopy, which was followed by chemotherapy.</p><p><strong>Results: </strong>The enterostomy and non-enterostomy groups included 20 and 27 patients, respectively. The chemotherapy regimens included SOX, SOX+nivolumab, SP, biweekly NAC-DCS, and XP+trastuzumab. Grade 3 or higher adverse events, including neutropenia, malaise, and diarrhea, were more common in the no-enterostomy group. The completion rates of at least 2 chemotherapy courses were similar between groups. Grade Ⅲa or higher complications during gastrectomy were slightly higher in the enterostomy group. The pathological responses were comparable between groups.</p><p><strong>Conclusion: </strong>Preoperative chemotherapy using enterostomy for advanced gastric cancer with obstructive symptoms showed efficacy and safety comparable to those of traditional methods, suggesting that it is a viable treatment option.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 4","pages":"363-365"},"PeriodicalIF":0.0000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Investigation of Preoperative Chemotherapy Using Enterostomy for Advanced Gastric Cancer with Stenosis].\",\"authors\":\"Hidetaka A Ono, Yohei Ota, Hirokazu Suwa, Kazunori Nojiri, Kenichi Yoshida, Hidenobu Masui, Kaoru Nagahori\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Preoperative chemotherapy for gastric cancer with obstructive symptoms traditionally requires bypass surgery.</p><p><strong>Objective: </strong>To investigate the feasibility of preoperative enterostomy chemotherapy in patients with advanced gastric cancer who present with obstructive symptoms.</p><p><strong>Methods: </strong>A total of 47 patients with cStage Ⅲ gastric cancer who underwent preoperative chemotherapy between April 2013 and May 2024 were included. Patients with circumferential lesions underwent enterostomy during diagnostic laparoscopy, which was followed by chemotherapy.</p><p><strong>Results: </strong>The enterostomy and non-enterostomy groups included 20 and 27 patients, respectively. The chemotherapy regimens included SOX, SOX+nivolumab, SP, biweekly NAC-DCS, and XP+trastuzumab. Grade 3 or higher adverse events, including neutropenia, malaise, and diarrhea, were more common in the no-enterostomy group. The completion rates of at least 2 chemotherapy courses were similar between groups. Grade Ⅲa or higher complications during gastrectomy were slightly higher in the enterostomy group. The pathological responses were comparable between groups.</p><p><strong>Conclusion: </strong>Preoperative chemotherapy using enterostomy for advanced gastric cancer with obstructive symptoms showed efficacy and safety comparable to those of traditional methods, suggesting that it is a viable treatment option.</p>\",\"PeriodicalId\":35588,\"journal\":{\"name\":\"Japanese Journal of Cancer and Chemotherapy\",\"volume\":\"52 4\",\"pages\":\"363-365\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Japanese Journal of Cancer and Chemotherapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Japanese Journal of Cancer and Chemotherapy","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
[Investigation of Preoperative Chemotherapy Using Enterostomy for Advanced Gastric Cancer with Stenosis].
Background: Preoperative chemotherapy for gastric cancer with obstructive symptoms traditionally requires bypass surgery.
Objective: To investigate the feasibility of preoperative enterostomy chemotherapy in patients with advanced gastric cancer who present with obstructive symptoms.
Methods: A total of 47 patients with cStage Ⅲ gastric cancer who underwent preoperative chemotherapy between April 2013 and May 2024 were included. Patients with circumferential lesions underwent enterostomy during diagnostic laparoscopy, which was followed by chemotherapy.
Results: The enterostomy and non-enterostomy groups included 20 and 27 patients, respectively. The chemotherapy regimens included SOX, SOX+nivolumab, SP, biweekly NAC-DCS, and XP+trastuzumab. Grade 3 or higher adverse events, including neutropenia, malaise, and diarrhea, were more common in the no-enterostomy group. The completion rates of at least 2 chemotherapy courses were similar between groups. Grade Ⅲa or higher complications during gastrectomy were slightly higher in the enterostomy group. The pathological responses were comparable between groups.
Conclusion: Preoperative chemotherapy using enterostomy for advanced gastric cancer with obstructive symptoms showed efficacy and safety comparable to those of traditional methods, suggesting that it is a viable treatment option.